Stockreport

Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

Mustang Bio, Inc.  (MBIO) 
Last mustang bio, inc. earnings: 11/12 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: mustangbio.com/investor-relations
PDF Initial data show clinical responses from four of four indolent lymphoma patients, including complete response in follicular lymphoma patient previously treated with CD1 [Read more]